UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of earliest event reported): June 25, 2020

 

JANONE INC.

(Exact Name of Registrant as Specified in Charter)

 

 

Nevada

000-19621

41-1454591

(State or Other Jurisdiction

of Incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

 

325 E. Warm Springs Road, Suite 102

Las Vegas, NV 89119

(Address of Principal Executive Offices and Zip Code)

 

Registrant’s telephone number, including area code: 702-997-5968

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading

Symbol(s)

 

Name of each exchange on which registered

Common Stock, $0.001 par value per share

 

JAN

 

The NASDAQ Stock Market LLC

(The NASDAQ Capital Market)

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company   

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. 

 

 

 

 


 

Item 8.01 Other Events.

 

On June 25, 2020, JanOne Inc. (the “Company”) issued a press release announcing the addition of  Douglas Flanagan, Ph.D. as the Company’s chief formulation advisor.

 

 

A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.

Item 9.01. Financial Statements and Exhibits

(d)        Exhibits

 

Exhibit

Number

 

Description

 

 

 

99.1

 

Press Release of JanOne Inc., dated June 25, 2020

 

2


 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, we have duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

JanOne Inc.

 

 

By:

/s/ Tony Isaac

 

Name:  Tony Isaac

 

Title:    Chief Executive Officer

 

Dated:  June 25, 2020

 

3

jan-ex991_7.htm

Exhibit 99.1

 

FOR IMMEDIATE RELEASE

 

JanOne taps distinguished chemist Dr. Doug Flanagan as chief formulation advisor

 

Dr. Flanagan, an accomplished chemist and formulation specialist, leads manufacturing and clinical development of JanOne’s PAD candidate TV1001SR

 

LAS VEGAS, NV, June 25, 2020 - JanOne Inc. (NASDAQ: JAN), a company focused on bringing treatments to market for conditions that cause severe pain and drugs with non-addictive pain relieving properties, continues to build a world-class team of biopharma experts with the addition of  Douglas Flanagan, PhD as the company’s chief formulation advisor. Dr. Flanagan will work directly with CoreRX, JanOne’s manufacturing partner to ensure the integrity of TV1001SR, the company’s clinical candidate for treating Peripheral Artery Disease (PAD) expected soon to enter phase 2 trials. He will also play an integral role for the potential identification and advancement of other clinical candidates to treat pain as the company hopes to broaden its pipeline in the near future.

 

According to Tony Isaac, JanOne’s chief executive officer, “We are confident that Dr. Flanagan’s extensive accomplishments as a researcher, chemist and formulation advisor to some of the world’s leading biopharma companies will ensure proper formulation of our clinical candidates. We welcome his expertise and look forward to his contribution to our future success.”  

 

Dr. Flanagan brings over 40 years of scientific, pharmaceutical formulation and clinical experience and has published over 90 peer reviewed articles and delivered over 150 presentations, talks and lectures around the world. He has lent his formulation expertise to over 50 pharmaceutical companies and medical organizations including Abbott Laboratories, Pfizer Animal Health (spun off as Zoetis), Bristol Myers Squibb, the World Health Organization and the Federal Drug Administration(FDA) to name a few. In addition to serving as an expert witness to successfully litigate various pharmaceutical patents, Dr. Flanagan also holds various formulation patents, including pharmaceutical formulations of nitrite, a key component of TV1001SR. Dr. Flanagan was appointed as Emeritus Professor at the University of Iowa College of Pharmacy where he served as a faculty member for 34 years.

 

Dr Flanagan commented, “I am pleased to advise the team at JanOne. I hope to help accelerate treatments for diseases that cause severe pain such as PAD. I also share in the company’s ultimate mission to reduce the need for opioid prescriptions by bringing to market non-addictive pain relieving formulations.”

 

About JanOne

JanOne is a unique NASDAQ-listed company that is focused on bringing medications to market to treat diseases that cause severe pain in an effort to reduce the need for prescriptions opioids often used to treat disease associated pain. The company is also exploring solutions for non-addictive pain medications. The lead candidate is for treating peripheral artery disease (PAD), a condition that affects over 8.5 million Americans, with plans currently underway for phase 2b trials. JanOne is currently dedicated to funding resources toward innovation, technology, and education for PAD and neuropathic pain. The company continues to operate its legacy businesses, ARCA Recycling and GeoTraq, under their current brand names. ARCA Recycling provides turnkey recycling and replacement services for utilities and other sponsors of energy efficiency programs. GeoTraq engages in the development, design and,

 


Exhibit 99.1

 

ultimately, the company expects, sale of Mobile IoT modules. Please visit www.janone.com for additional information.

 

Forward-Looking Statements

This press release contains statements that are forward-looking statements as defined within the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements relating to the company’s expectation that TV1001SR will soon enter phase 2 trials, the identification of other potential candidates to treat pain, and other statements including words such as “continue”, “expect”, “intend”, “will”, “hope” “should”, “would”, “may”, “potential” and other similar expressions. Such statements reflect our current views with respect to future events and are subject to risks and uncertainties and are necessarily based upon a number of estimates and assumptions that, while considered reasonable by us, are inherently subject to significant business, economic, competitive, political and social uncertainties, and contingencies. Many factors could cause our actual results, performance or achievements to be materially different from any future results, performance or achievements described in this press release. Such factors could include, among others, those detailed in the Company’s periodic reports filed with the Securities and Exchange Commission (the “SEC”).

 

Should one or more of these risks or uncertainties materialize, or should the assumptions set out in the section entitled “Risk Factors” in our filings with the SEC underlying those forward-looking statements prove incorrect, actual results may vary materially from those described herein. These forward-looking statements are made as of the date of this press release and we do not intend, and do not assume any obligation, to update these forward-looking statements, except as required by law. We cannot assure you that such statements will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. Investors are cautioned that forward-looking statements are not guarantees of future performance and accordingly investors are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty therein.

 

###

 

Media contact:

Mark Rosenberg | mark@trueparallel.com | 919-412-7378